OIPE

RAW SEQUENCE LISTING   DATE: 05/14/2001
PATENT APPLICATION: US/09/847,670   TIME: 12:42:47

Input Set : A:\26862631.app
Output Set: N:\CRF3\05142001\I847670.raw

ENTERED

```
      3 <110> APPLICANT: PHARMACIA & UPJOHN COMPANY
      5 <120> TITLE OF INVENTION: HEPATITUS C VIRUS HELICASE CRYSTALS, CRYSTALLOGRAPHIC
      6       STRUCTURE AND METHODS
      8 <130> FILE REFERENCE: 6263.N
C--> 10 <140> CURRENT APPLICATION NUMBER: US/09/847,670
     11 <141> CURRENT FILING DATE: 2001-05-02
     13 <150> PRIOR APPLICATION NUMBER: 60/201,598
     14 <151> PRIOR FILING DATE: 2000-05-03
     16 <160> NUMBER OF SEQ ID NOS: 3
     18 <170> SOFTWARE: PatentIn Ver. 2.1
     20 <210> SEQ ID NO: 1
     21 <211> LENGTH: 473
     22 <212> TYPE: PRT
     23 <213> ORGANISM: Hepatitis C virus
     25 <400> SEQUENCE: 1
     26 Met Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser
     27  1               5                  10                  15
     29 Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe
     30             20                  25                  30
     32 Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys
     33             35                  40                  45
     35 Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn
     36         50                  55                  60
     38 Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala
     39 65                  70                  75                  80
     41 His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr
     42             85                  90                  95
     44 Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly
     45             100                 105                 110
     47 Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His
     48         115                 120                 125
     50 Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln
     51     130                 135                 140
     53 Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro
     54 145                 150                 155                 160
     56 Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu
     57             165                 170                 175
     59 Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu
     60             180                 185                 190
     62 Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys
     63             195                 200                 205
     65 Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val
     66     210                 215                 220
     68 Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp
     69 225                 230                 235                 240
     71 Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp
     72             245                 250                 255
```

RAW SEQUENCE LISTING   DATE: 05/14/2001
PATENT APPLICATION: US/09/847,670   TIME: 12:42:47

Input Set : A:\26862631.app
Output Set: N:\CRF3\05142001\I847670.raw

```
 74 Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp
 75             260             265             270
 77 Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu Pro Gln
 78          275             280             285
 80 Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys
 81      290             295             300
 83 Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met
 84 305             310             315             320
 86 Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp
 87             325             330             335
 89 Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met
 90             340             345             350
 92 Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu
 93          355             360             365
 95 Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln
 96      370             375             380
 98 Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala
 99 385             390             395             400
101 Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met
102             405             410             415
104 Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro
105             420             425             430
107 Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His
108          435             440             445
110 Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val
111      450             455             460
113 Val Thr Ser His His His His His His
114 465             470
117 <210> SEQ ID NO: 2
118 <211> LENGTH: 9
119 <212> TYPE: PRT
120 <213> ORGANISM: Hepatitis C virus
122 <400> SEQUENCE: 2
123 Pro Thr Gly Ser Gly Lys Ser Thr Lys
124   1               5
127 <210> SEQ ID NO: 3
128 <211> LENGTH: 8
129 <212> TYPE: PRT
130 <213> ORGANISM: Artificial Sequence
132 <220> FEATURE:
133 <223> OTHER INFORMATION: Description of Artificial Sequence: conserved
134        sequence motif VI wherein Xaa represents
135        unconserved amino acids within the motif
137 <400> SEQUENCE: 3
138 Gln Arg Xaa Gly Arg Xaa Gly Arg
139   1               5
```

W-->

VERIFICATION SUMMARY DATE: 05/14/2001
PATENT APPLICATION: **US/09/847,670** TIME: 12:42:48

Input Set : **A:\26862631.app**
Output Set: **N:\CRF3\05142001\I847670.raw**

L:10 M:270 C: Current Application Number differs, Replaced Current Application Number
L:138 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:3
L:138 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:3
L:138 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3